- 1,636studies in the library match, of 29,380
- 718name it in the title
- 1977–2026years published
- 1,598peer-reviewed articles
The query: title or abstract mentions "frontotemporal", "FTD", "FTLD", "Pick's disease", "primary progressive aphasia", "C9orf72", "progranulin" or "GRN", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,380 study records, as of 2026-11-08. Every count on this page comes from that match. The matched list as JSON.
FTD is a group of conditions in which the frontal and temporal lobes shrink. The behavioural variant changes personality, judgement and empathy; the language variants (primary progressive aphasia) affect speech and word meaning. It is the most common dementia in people under 60, and a sizeable share is inherited, through mutations in genes such as C9orf72, GRN and MAPT. The proteins involved are tau or TDP-43, not amyloid.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 1,636 matched records are quoted; each links to its study page and from there to the paper.
“Rare variant association analysis between patients and controls showed no difference over the whole protein, but suggested that rare mutations clustering in the UBA domain of SQSTM1 may influence disease susceptibility by doubling the risk for FTLD (RR = 2.18 [95 % CI 1.24-3.85]; corrected p value = 0.042).”
“Results A total of 27 participants (mean [SD] age, 56.6 [10.5] years; 16 women [59.3%]; 26 White participants [96.3%]) with GRN variations were randomized and completed treatment.”
“In addition, the finding in the stage 1 sample that AD risk is significantly influenced by the interaction of APOE with rs1595014 in TMEM106B (P=1·6 × 10(-7)) is noteworthy, because TMEM106B variants have previously been associated with risk of frontotemporal dementia.”
“A case-control meta-analysis of all published E117G ALS+/- frontotemporal dementia cases including those identified in this report was significant p = 0.001, odds ratio = 3.26 (95% confidence interval, 1.6-6.7), demonstrating this variant to be a susceptibility allele.”
“Mutations in three genes-MAPT, GRN, and C9orf72--have been associated with FTD.”
“Results Plasma p-tau 217 effectively distinguished AD from FTLD, with the NfL/p-tau 217 ratio showing superior accuracy.”
“We confirm UNC13A as the strongest overall FTLD-TDP risk factor and identify TNIP1 as a novel FTLD-TDP risk factor.”
“We aimed to investigate the role of p.R47H variant in AD and FTD through a multi-center study comprising 3172 AD and 682 FTD patients and 2169 healthy controls from Spain.”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 47 |
| Randomised controlled trial | 2 |
| Other clinical trial | 5 |
| Cohort or longitudinal study | 108 |
| Case-control study | 14 |
| Cross-sectional study | 49 |
| Other recorded design | 7 |
| No design recorded | 1,404 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 117 | |
| 2025 | 262 | |
| 2024 | 37 | |
| 2023 | 53 | |
| 2022 | 71 | |
| 2021 | 66 | |
| 2020 | 64 | |
| 2019 | 72 | |
| 2018 | 69 | |
| 2017 | 63 | |
| 2016 and earlier | 762 |
Other counts within the matched set
| Peer-reviewed articles | 1,598 |
| Marked open access in the record | 576 |
| Rated "high" evidence strength in alzhub's summary | 57 |
| Rated "moderate" evidence strength in alzhub's summary | 270 |
| Rated "low" evidence strength in alzhub's summary | 1,304 |
| No evidence-strength rating | 5 |
| Records stating a participant count | 530 |
| Median participants (those records) | 95 |
| Largest participant count | 1,333,424 |
Within the 1,636 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that mention a gene (C9orf72, GRN/progranulin, MAPT) | 313 | the abstract also contains "C9orf72", "progranulin", "GRN" or "MAPT" |
| …that mention TDP-43 | 318 | the abstract also contains "TDP-43" |
| …that also mention Alzheimer's | 891 | the abstract also contains "Alzheimer" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration
- Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial
- Cognitive reserve in individuals with frontotemporal dementia: a systematic review
- Frontotemporal dementia and its subtypes: a genome-wide association study
- Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study
- Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia
- Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration
- Plasma p-tau217 and neurofilament/p-tau217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration
- The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease
- Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing
Systematic reviews and meta-analyses in the set
47 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- A novel Alzheimer disease locus located near the gene encoding tau protein
- Novel mutations support a role for Profilin 1 in the pathogenesis of ALS
- Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations
- Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia
- Blood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review
Newest matched studies
- From group-level neurophysiological biomarkers to individual-level phenotyping to identify mechanisms of neurodegenerative disease
- Beyond reduced alpha power: a weaker temporal link between alpha and other brain rhythms in Alzheimer’s disease
- A Dual-Stream Spatio-Temporal Network with Bidirectional Rectification for Differential Diagnosis of Dementia using EEG
- Frequency-Resolved Connectivity Graphs for EEG-Based Classification of Alzheimer and Frontotemporal Dementia
- Normative transcriptomic clues to thalamic developmental vulnerability in C9orf7 2-FTLD
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Neurology | 98 |
| Brain : a journal of neurology | 60 |
| Acta neuropathologica | 56 |
| Annals of neurology | 34 |
| Alzheimer s & Dementia | 33 |
Questions
- How is frontotemporal dementia different from Alzheimer's?
- It tends to start earlier, often in the fifties or sixties, and the first changes are usually in behaviour, personality or language rather than memory. The proteins involved are tau or TDP-43 rather than amyloid, so amyloid tests are typically negative.
- How many studies on frontotemporal dementia does alzhub hold?
- 1,636 of the 29,380 study records in alzhub's library match the query "title or abstract mentions "frontotemporal", "FTD", "FTLD", "Pick's disease", "primary progressive aphasia", "C9orf72", "progranulin" or "GRN""; 718 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 47 systematic review or meta-analysis, 2 randomised controlled trials, 5 other clinical trials, 108 cohort or longitudinal studys, 14 case-control studys, 49 cross-sectional studys; 1,404 record no design.
- What is the most recent study in the set?
- "From group-level neurophysiological biomarkers to individual-level phenotyping to identify mechanisms of neurodegenerative disease" (bioRxiv, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Neurology (98); Brain : a journal of neurology (60); Acta neuropathologica (56), counted across the matched records.
Read on
- Getting a diagnosisWhat the diagnostic process involves.
- Lewy body dementia vs Alzheimer'sAnother non-Alzheimer's dementia.
- GlossaryTerms explained in plain English.